AU2007317306B2 - SPINK1 as a prostate cancer marker and uses thereof - Google Patents

SPINK1 as a prostate cancer marker and uses thereof Download PDF

Info

Publication number
AU2007317306B2
AU2007317306B2 AU2007317306A AU2007317306A AU2007317306B2 AU 2007317306 B2 AU2007317306 B2 AU 2007317306B2 AU 2007317306 A AU2007317306 A AU 2007317306A AU 2007317306 A AU2007317306 A AU 2007317306A AU 2007317306 B2 AU2007317306 B2 AU 2007317306B2
Authority
AU
Australia
Prior art keywords
expression
spinki
prostate
erg
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007317306A
Other languages
English (en)
Other versions
AU2007317306A1 (en
Inventor
Arul M. Chinnaiyan
Rohit Mehra
Daniel R. Rhodes
Scott A. Tomlins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of AU2007317306A1 publication Critical patent/AU2007317306A1/en
Application granted granted Critical
Publication of AU2007317306B2 publication Critical patent/AU2007317306B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor or ovomucoid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2007317306A 2006-11-08 2007-11-08 SPINK1 as a prostate cancer marker and uses thereof Ceased AU2007317306B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85775806P 2006-11-08 2006-11-08
US60/857,758 2006-11-08
US90687607P 2007-03-14 2007-03-14
US60/906,876 2007-03-14
PCT/US2007/084090 WO2008058239A2 (en) 2006-11-08 2007-11-08 Spink1 as a prostate cancer marker and uses thereof

Publications (2)

Publication Number Publication Date
AU2007317306A1 AU2007317306A1 (en) 2008-05-15
AU2007317306B2 true AU2007317306B2 (en) 2012-06-14

Family

ID=39365376

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007317306A Ceased AU2007317306B2 (en) 2006-11-08 2007-11-08 SPINK1 as a prostate cancer marker and uses thereof

Country Status (8)

Country Link
US (1) US20100129804A1 (enExample)
EP (1) EP2079851B1 (enExample)
JP (2) JP2010508855A (enExample)
CN (2) CN101652484B (enExample)
AU (1) AU2007317306B2 (enExample)
CA (1) CA2668961A1 (enExample)
IL (2) IL198526A (enExample)
WO (1) WO2008058239A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011102999A2 (en) * 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Spink1 targeted therapy
CA2795242C (en) * 2010-04-02 2019-08-13 Veridex, Llc Gene-based prediction of psa recurrence for clinically localized prostate cancer patients
WO2012078752A2 (en) * 2010-12-09 2012-06-14 Philadelphia Health & Education Corporation D/B/A Serine protease inhibitor kazal antibodies
EP3348652B1 (en) * 2011-05-12 2023-07-26 MDxHealth Research B.V. Molecular markers in prostate cancer
EP2748335B1 (en) * 2011-08-22 2018-10-03 Exosome Diagnostics, Inc. Urine biomarkers
WO2013036755A1 (en) * 2011-09-09 2013-03-14 Sloan-Kettering Institute For Cancer Research Etv1 antibodies and uses thereof
EP2786151B1 (en) * 2011-11-29 2019-07-03 F.Hoffmann-La Roche Ag Methods for prostate cancer analysis
CN103436594A (zh) * 2012-10-16 2013-12-11 科蒂亚(新乡)生物技术有限公司 一种bdna在尿液中检测pca3的应用
CN102968558B (zh) * 2012-11-14 2015-11-18 叶定伟 一种预测初诊前列腺癌骨转移风险的装置
WO2016087430A1 (en) * 2014-12-01 2016-06-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel RNA-biomarker signature for diagnosis of prostate cancer
CN104531878B (zh) * 2015-01-04 2017-11-10 上海市同济医院 一种联合lncRNA和AR3检测试剂盒及应用
CN105717082A (zh) * 2016-02-02 2016-06-29 管晓翔 一种用于检测三阴性乳腺癌瘤内异质性的方法
KR101948385B1 (ko) * 2016-09-01 2019-05-13 충북대학교 산학협력단 전립선암 예후 분석용 신규 바이오마커 및 그의 용도
CN109521457B (zh) * 2018-09-25 2022-10-21 中国辐射防护研究院 一种基于信息准则的γ辐射源项划分方法及系统
CN111110849B (zh) * 2018-10-11 2021-09-10 中国科学院上海营养与健康研究所 丝氨酸蛋白酶抑制因子Kazal 1型在制备细胞衰老及肿瘤诊断或调控制剂中的应用
CN109678950B (zh) * 2019-01-08 2022-05-10 灏灵赛奥（天津）生物科技有限公司 spink1抗原、能够特异性结合spink1的抗体及其功能片段及其应用和产品
CN109776679B (zh) * 2019-01-08 2022-06-17 灏灵赛奥（天津）生物科技有限公司 一种丝氨酸蛋白酶抑制因子spink1的抗体、其制备方法和应用
US11788091B2 (en) 2019-08-21 2023-10-17 University Of Virginia Patent Foundation Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
US12319967B2 (en) 2019-08-21 2025-06-03 University Of Virginia Patent Foundation Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
CN111308095A (zh) * 2020-03-04 2020-06-19 北京师范大学 用于诊断前列腺癌的尿液蛋白标记物
EP4232605A4 (en) * 2020-11-11 2024-09-25 University of Virginia Patent Foundation METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING PROSTATE CANCER BASED ON LONG NON-CODING RNA OVERLAPPING THE LCK GENE REGULATING PROSTATE CANCER CELL GROWTH
JPWO2023276768A1 (enExample) * 2021-06-29 2023-01-05
CN115181801A (zh) * 2022-07-11 2022-10-14 中山大学附属第一医院 Bhlhe22在前列腺癌骨转移免疫治疗中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323546A (en) * 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
JP3448090B2 (ja) * 1994-02-16 2003-09-16 浜松ホトニクス株式会社 エネルギー移動検出法およびその装置
US20050214309A1 (en) * 1994-03-18 2005-09-29 Hinrichs Steven H Methods and compositions for modulating transcription factor activity
US5854206A (en) * 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
EP0914335A2 (en) * 1996-03-15 1999-05-12 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
EP1005546A2 (en) * 1997-02-25 2000-06-07 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
ES2324503T3 (es) * 1997-04-10 2009-08-07 Stichting Katholieke Universiteit University Medical Centre Nijmegen Pca3, genes pca3 y metodos de uso.
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US6828429B1 (en) * 1999-03-26 2004-12-07 Henry M. Jackson Foundation For The Advancement Of Military Medicine Prostate-specific gene, PCGEM1, and the methods of using PCGEM1 to detect, treat, and prevent prostate cancer
CA2423154A1 (en) * 2000-09-21 2002-03-28 David Kenneth Dean Imidazole derivatives as raf kinase inhibitors
US6897024B2 (en) * 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US7217807B2 (en) * 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
KR20060031809A (ko) * 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
WO2005026687A2 (en) * 2003-09-05 2005-03-24 Thomas Jefferson University Diagnosis and monitoring of hepatocellular carcinoma
CN101018874A (zh) * 2004-08-13 2007-08-15 千年药品公司 用于鉴定、评估、预防和治疗前列腺癌的基因、组合物、试剂盒和方法
US20060275794A1 (en) * 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US7718369B2 (en) * 2005-09-12 2010-05-18 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
EP2074225B1 (en) * 2006-10-10 2014-12-03 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations
WO2009044899A1 (ja) * 2007-10-03 2009-04-09 Kyowa Hakko Kirin Co., Ltd. 細胞の増殖を制御する核酸

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Singh et al, Cancer Letters, 2006, vol 237(2): 298-304 *

Also Published As

Publication number Publication date
CN101652484B (zh) 2013-03-20
WO2008058239A2 (en) 2008-05-15
CN103233063A (zh) 2013-08-07
WO2008058239A9 (en) 2009-12-23
IL215373A (en) 2013-07-31
CA2668961A1 (en) 2008-05-15
EP2079851A2 (en) 2009-07-22
US20100129804A1 (en) 2010-05-27
CN101652484A (zh) 2010-02-17
EP2079851B1 (en) 2015-01-07
JP2010508855A (ja) 2010-03-25
JP2014087335A (ja) 2014-05-15
IL215373A0 (en) 2011-11-30
IL198526A0 (en) 2010-02-17
EP2079851A4 (en) 2010-09-01
AU2007317306A1 (en) 2008-05-15
JP5850898B2 (ja) 2016-02-03
WO2008058239A3 (en) 2008-11-06
IL198526A (en) 2012-10-31

Similar Documents

Publication Publication Date Title
AU2007317306B2 (en) SPINK1 as a prostate cancer marker and uses thereof
EP3018216B1 (en) Recurrent gene fusions in prostate cancer
AU2006291054B2 (en) Recurrent gene fusions in prostate cancer
US9957569B2 (en) Recurrent gene fusions in prostate cancer
EP2430191B1 (en) Phosphodiesterase 4d7 as prostate cancer marker
AU2010295689B2 (en) Recurrent gene fusions in prostate cancer
JP2009508493A (ja) すい臓がんを診断するための方法
US20170081731A1 (en) Raf gene fusions
HK1187055A (en) Recurrent gene fusions in prostate cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired